Contribution of APCs to mucosal-associated invariant T cell activation in infectious disease and cancer

Muki Shehu Shey1,2 ©, Avuyonke Balfour1,2, Katalin Andrea Wilkinson1,2,3 and Graeme Meintjes1,2

Abstract
APCs such as monocytes and dendritic cells are among the first cells to recognize invading pathogens and initiate an immune response. The innate response can either eliminate the pathogen directly, or through presentation of Ags to T cells, which can help to clear the infection. Mucosal-associated invariant T (MAIT) cells are among the unconventional T cells whose activation does not involve the classical co-stimulation during Ag presentation. MAIT cells can be activated either via presentation of unconventional Ags (such as riboflavin metabolites) through the evolutionarily conserved major histocompatibility class I-like molecule, MR1, or directly by cytokines such as IL-12 and IL-18. Given that APCs produce cytokines and can express MR1, these cells can play an important role in both pathways of MAIT cell activation. In this review, we summarize evidence on the role of APCs in MAIT cell activation in infectious disease and cancer. A better understanding of the interactions between APCs and MAIT cells is important in further elucidating the role of MAIT cells in infectious diseases, which may facilitate the design of novel interventions such as vaccines.

Keywords
Antigen presenting cells, cancer, infectious disease, IL-12, IL-18, MAIT cell activation, MR1

Date received: 18 October 2017; revised: 9 March 2018; accepted: 13 March 2018

Introduction
Following a pathogenic infection, innate cells, especially APCs such as dendritic cells (DCs), monocytes/macrophages, and B cells recognize and initiate an immune response to eliminate the pathogen. The innate response can either eliminate the pathogen directly, or through presentation of Ags to T cells to activate the adaptive immune response that helps clear the infection.1 Unlike an innate response, the T cell response is typically delayed and develops several hours or days following infection and priming by innate cells.2 Several T cell subsets exist, including the conventional (CD4+ and CD8+) and the unconventional T cells or donor-unrestricted T cells (DURT) including gamma delta, NK T cells (NKT) and mucosal-associated invariant T (MAIT) cells.3 MAIT cells are T cells with innate-like functions and have recently gained much attention as important players in immunity to infectious diseases and in the pathogenesis of certain non-communicable diseases such as obesity, cancer, and diabetes. Unlike conventional T cells, which are activated solely through Ag presentation, MAIT cells can be activated either via Ag presentation through the evolutionarily conserved MHC class I (MHC-I)-like molecule, MR1, or directly by cytokines.4 Given that APCs produce cytokines and can express
MR1 necessary for Ag presentation, these cells play an important role in both pathways of MAIT cell activation. In this review, we summarize what is known and highlight the knowledge gaps regarding the role of conventional APCs such as monocytes and DCs in the activation of MAIT cells in peripheral blood and the tissue environment.

**MAIT cells: phenotype, location and function**

MAIT cells were first described in 1999, by the sequencing of their TCRs in purified CD8α⁺-enriched or CD8α⁻-depleted peripheral blood lymphocytes in humans. Similar cells were found in mice and cattle. It is only in the last 15 yr that the function of these cells has been described as research on MAIT cells has expanded due to their recognized role in anti-microbial immunity (Figure 1). MAIT cells are described as evolutionarily conserved T cells with innate-like properties and a limited T-cell receptor repertoire. These cells are primarily CD8⁺ or CD4 CD8⁺ (double negative), and a smaller subset are CD4⁺. Human MAIT cells express CD161 at high levels with co-expression of the invariable T cell receptor Vα7.2 or TRAV1-2. Co-expression of CD161 and CD26 has also been used to define these cells in humans. Recently, ligand-loaded MR1 tetramers have been developed, and may be used for more consistent identification of MAIT cells.

The specific vitamin B metabolites serving as MR1-restricted ligands for MAIT cell activation include the non-activating folic acid metabolite, 6-formyl pterin, and the highly potent riboflavin (vitamin B2) metabolite, reduced 6-hydroxymethyl-8-D-ribityllumazine (rRL-6-CH₂OH). When activated, MAIT cells can proliferate, produce cytokines (including IFN-γ, TNF-α, IL-17) and express cytotoxic molecules including granzymes, granulysin and perforin. The expression of cytotoxic molecules confers to MAIT cells the ability to directly kill pathogen-infected cells through lysis or apoptosis of infected cells. Some evidence suggested site-dependent differences in MAIT cell function in response to bacterial stimulation with MAIT cells from the female genital tract producing more IL-17 and IL-22, and less IFN-γ and TNF-α compared with MAIT cells in peripheral blood. Even though MAIT cells can be activated through the TCR-dependent (MR1) or independent (cytokine) pathways, the relative contribution from each of these pathways is not well defined, and likely depends on the pathogen eliciting the response. TCR-dependent activation of MAIT cells has been reported to arise early during stimulation, is short-lived, while long-term activation of effector MAIT cells is dependent on cytokines (TCR-independent). The degree of activation of tissue MAIT cells is limited (reflected in lower production of cytokines), even though these cells exhibit more rapid activation (reflected in broad up-regulation of gene expression) than blood MAIT cells, suggesting that the restriction of memory MAIT cell activation by TCR-dependent pathway in tissues is necessary to avoid unwanted activation in the absence of infection. Compared to other T cell subsets, MAIT cells have been shown to display primarily an effector memory phenotype (CCR7⁺CD45RA⁻) upon activation and in patients with active TB.

Recent reports suggest that, in contrast to their antimicrobial properties, MAIT cells can also induce immunopathology and immunosuppression in response to superantigens such as staphylococcal enterotoxin B (SEB). SEB induced an exaggerated and rapid cytokine production by MAIT cells compared to non-MAIT CD4⁺, CD8⁺, gamma-delta and invariant NK (iNK) T cells, resulting in up-regulation of programme death 1 (PD1), T cell immunoglobulin and mucin 3 (TIM3) and lymphocyte activation gene 3 (LAG-3), which rendered MAIT cells anergic to Klebsiella pneumoniae and E. coli stimulation. These MAIT cell responses to SEB were independent of MR1, but highly dependent on SEB-induced IL-12 and IL-18 production.

**APCs: Monocytes, DCs and B cells – function, location, and activation during pathogenic infection**

APCs are among the first cells to recognize invading pathogens and initiate an immune response. The major APCs are DCs, monocytes/macrophages and B cells. Three distinct DC subsets have been described, including plasmacytoid DCs (pDCs; CD14⁺CD123⁻CD11c⁻), myeloid DCs (mDCs; CD14⁺CD123⁺CD11c⁺), found in blood, and Langerhans cells (LCs; CD1a⁺ or langerin⁺; found in tissues), which differ in phenotypic and functional properties, including expression of different receptors for pathogen recognition and the type of cytokines produced. Monocytes in human blood have been subdivided into three subsets with different functions in inflammation: classical monocytes characterized by high level expression of CD14 and low expression of CD16 (CD14⁺CD16⁻), non-classical monocytes with medium level expression of CD14 and high expression of CD16 (CD14⁺CD16⁺), and intermediate...
Figure 1. Interactions between APCs and MAIT cells in health and disease. (a) In the absence of infection, APCs may still produce cytokines as part of housekeeping processes but not enough to activate MAIT cells. (b) During bacterial infection, APCs produce large amounts of cytokines able to activate MAIT cells in an MR1-independent manner (I) or MAIT cells are activated through Ag presentation on MR1 (II). MAIT cells produce effector molecules such as IFN-γ, TNF-α and cytotoxic molecules required for killing and eliminating bacteria-infected cells. (c) Viral infection results in cytokine-dependent activation of MAIT cells (I). MAIT cells produce effector molecules such as IFN-γ, TNF-α and cytotoxic molecules required for killing and eliminating virus-infected cells.
monocytes, characterized by low expression of CD16 and medium to high expression of CD14 (CD14<sup>+</sup>CD16<sup>+</sup> or CD14<sup>+</sup>CD16<sup>-</sup>).<sup>28,29</sup> Although the best-known function of B-cells is the Ab production leading to the formation of immune complexes that will help the clearance of microbes, B-cells are also considered to be classical APCs that can also directly influence MAIT responses via Ag presentation and cytokine production.<sup>30,31</sup> In addition, B cells and DCs also express lectin-like transcript-1 (LLT1), a ligand for CD161 used to identify MAIT cells.<sup>32–34</sup> B cells are essential for the development and maintenance of MAIT cells in humans and mice.<sup>35</sup>

APCs recognize pathogens through PRRs of which TLRs are the most widely studied. These receptors recognize PAMPs derived from microbial pathogens or danger-associated molecular patterns (DAMPs, also known as alarmins) derived from stressed cells and tissue injury, to initiate an immune response. The type of PRR initially triggered may determine the outcome of an innate immune response. This initial innate response may dictate the subsequent type of adaptive immune response mounted in response to an infection. Activated APCs produce cytokines and up-regulate expression of HLA class I/II and co-stimulatory molecules (including CD86, CD80 and CD40).<sup>36</sup> Upon phagocytosis of pathogens such as mycobacteria including Mtb, APCs may eliminate the pathogens by either direct killing (for example via degradation in the lysosome),<sup>37</sup> and/or presentation of Ags derived from these pathogens to activate T cells. Three signals are required to activate conventional T cells during Ag presentation: (a) binding of the Ag-MHC complex with the T cell receptor (Signal 1); (b) the binding of the co-stimulatory molecules (such as CD80, CD86) on APC with CD28 on T cells (Signal 2); and (c) the production of cytokines by APCs that act on T cells (Signal 3).<sup>38</sup> Activated T cells including CD4<sup>+</sup> and CD8<sup>+</sup> cells produce cytokines such as IFN-γ, or cytotoxic molecules such as granzymes or perforins. IFN-γ can activate innate cells to kill the pathogen through the production of NO products, and cytotoxic molecules can directly kill infected cells.<sup>39,40</sup>

Among the cytokines produced by APCs with diverse immune functions are IL-12 and IL-18, which are involved in activation of T cells including MAIT cells (discussed below). IL-12 plays a major role in polarization of T cell immunity towards a T helper type 1 (Th1) phenotype during Ag presentation in pathogenic infections including HIV and TB.<sup>41–43</sup> IL-12 has been shown to enhance CD4<sup>+</sup> and CD8<sup>+</sup> immune responses in HIV infection; and IL-12-mediated Ag-specific T cell proliferation was correlated with the stage of chronic HIV infection.<sup>44</sup> Elevated levels of IL-18 have been described in patients with HIV infections possibly contributing to sustained immune activation in this group of patients.<sup>45</sup> Experiments in animal models demonstrated the importance of IL-12 and IL-18 in immune responses to TB, with mice lacking these cytokines unable to control Mtb infection.<sup>42,46</sup> Sustained IFN-γ immune responses necessary for the control of TB are often mediated by IL-12.<sup>47</sup>

**MAIT cell activation and regulation by APCs**

Unlike conventional CD4<sup>+</sup> and CD8<sup>+</sup> T cells, MAIT cells can be activated in two different ways (Table 1): (a) activation through Ag presentation to MAIT cells on MR1 in a TCR-dependent manner; (b) direct activation in a TCR-independent manner by cytokines (such as IL-12, IL-15, IL-18) produced by pathogen-infected/activated innate cells. Different pathogens activate MAIT cells through one or both of the above-mentioned ways. Viruses activate MAIT cells through cytokines in a TCR-independent manner, as these pathogens lack the Ags in their metabolic pathways required to activate MAIT cells through MR1 Ag presentation.<sup>48</sup> Unlike viruses, most bacteria can activate MAIT cells through Ag presentation and cytokines. DCs and monocytes infected with BCG can produce cytokines including IL-12 and IL-18,<sup>49</sup> as well as degrade the bacteria to Ags that may be presented by MR1 to MAIT cells for activation.<sup>4</sup> Several other signaling pathways are involved in regulation of MAIT cell activation including PD-1 and signaling via TLRs on innate cells that result in the production of the cytokines that activate MAIT cells.<sup>50,51</sup> The relative contribution to MAIT cell activation from each of these pathways and Ag presentation to TCRs has not been defined.

The involvement of MR1 in MAIT cell activation was demonstrated by blocking MR1 or using MR1-deficient mice to show that MAIT cell responses to bacterial stimulations are significantly reduced (Table 1).<sup>4,12</sup> In most experiments to date, MAIT cell activation through MR1 or the MR1 expression has been evaluated in non-primary cells, MR1-transfected cell lines or epithelial cells.<sup>12,51</sup> Compared to MR1-transfected cell lines, MR1 expression on primary innate cells is suggested to be transient and this may result in lower frequencies (compared to MR1-transfected cells) of activated cytokine-producing MAIT cells upon stimulation with bacteria.<sup>50,52</sup> MR1 is localized in intracellular vesicles in primary APCs and relocates to the cell surface following binding of Ag or infection of cells.<sup>51</sup> MR1 expression on B cells (cell line) and epithelial cells has been shown to be significantly up-regulated after infection with different species of enteric bacteria (E. coli strains and Salmonella enterica serovar typhi (S. typhi)).<sup>53</sup>

Few studies have reported the role of DCs, monocytes and B cells in activation of MAIT cells. When MAIT cells were co-cultured with DCs and
| Pathogen type or disease | Pathways of MAIT cell activation | Experimental system | Major findings | References |
|--------------------------|----------------------------------|---------------------|---------------|------------|
| Mtb (TB)                 | MR1                              | PBMC-derived (CD8\(^+\) and CD8\(^-\)CD4\(^-\)) MAIT cells co-cultured with Mtb-infected A549 cell lines | Mtb-reactive MAIT cell clones were broadly reactive, enriched in lungs and detected Mtb-infected epithelial cells | 12 |
|                          |                                  | Co-culture of Mtb-infected DC or epithelial cells with MR1-restricted T cell clone (D426B1) | Mtb-infected lung epithelial cells efficiently stimulated IFN-γ release by MAIT cells | 51 |
| BCG                      | MR1 (regulated by PD-1 signaling) | PBMC stimulated with live BCG | MAIT cells from TB patients exhibited an increase (and a decrease) in IFN-γ production in response to BCG (and E. coli) respectively. | 23 |
|                          |                                  | Knockout mice, in vivo | MAIT cells inhibited intracellular BCG growth in macrophages | 4 |
|                          | MR1\(^a\)                        | MR1 tetramer in macaques | BCG vaccination induced MAIT cell activation at site of vaccination | 59 |
| E. coli                  | MR1 and IL-12p40\(^*\)           | PBMC cultured with cytokines and PBMC-derived V\(^α\)7.2\(^+\) cells co-cultured with E. coli-activated monocytes | MAIT cells were activated by E. coli-pulsed monocytes | 55, 60 |
|                          | Mainly MR1                       | THP1 cells co-cultured with CD8\(^+\) MAIT cells | Licensed MAIT cells killed E. coli-infected cells via granzyme B. | 10 |
|                          | Mainly IL-12/IL-18 with MR1 \(^a\) contribution | PBMC-derived CD8\(^+\) (MAIT) cells | Both CD161\(^+\)V\(^α\)7.2\(^+\) MAIT and CD161\(^+\)V\(^α\)7.2\(^+\) non-MAIT CD8\(^+\) cells responded to cytokine stimulation | 22 |
| Candida albicans         | MR1                              | PBMC-derived V\(^α\)7.2\(^+\) cells co-cultured with C. albicans-activated monocytes | MAIT cells responded to C. albicans and E. coli using distinct TCRs | 60 |
| Enteric bacteria         | MR1                              | B cell-line and primary B cells infected with enteric bacteria were co-cultured with primary MAIT cells in PBMC | MAIT cells were activated in an MR1-dependent manner to produce cytokines, and express CD107a/b and CD69 | 53 |
| (E. coli strains, S. typhi) |                                  | Healthy volunteers infected with S. typhi and followed up for 28 d for development of typhoid fever | MAIT cell numbers decreased in volunteers who developed disease, with a simultaneous increase in MAIT cell cytokine production, activation and proliferation | 61 |
| S. typhi                 |                                  | H. pylori-infected macrophages co-cultured with blood or gastric tissue-derived MAIT cells | MAIT cells were activated in an MR1-dependent manner resulting in production of cytokines, expression of CD107a and CD69, and killing of infected macrophages | 56 |
| H. pylori                |                                  | H. pylori-infected macrophages | MAIT cells were activated in an MR1-dependent manner resulting in production of cytokines, expression of CD107a and CD69, and killing of infected macrophages | 48 |
| HCV                     | IL-18 in synergy with IL-12, IL-15 and IFN-α/β | Co-culture of PBMC-derived CD8\(^+\) MAIT cells with HCV-infected macrophages | HCV-activated MAIT cells restricted HCV replication | 48 |
|                          | IL-18 in synergy with IL-12 and IFN-α | Culture of PBMC with IL-12/IL-18 or IL18/IFN-α | MAIT cells frequencies were reduced in chronic HCV infection even after successful treatment. | 62 |
| DENV                    | IL-18 in synergy with IL-12, IL-15 and IFN-α/β | Co-culture of PBMC-derived CD8\(^+\) MAIT cells with DENV-infected DCs | MAIT cells were activated by DENV to produce IFN-γ and granzyme B | 48 |

(Continued)
macrophages infected with hepatitis C virus (HCV), Dengue virus (DENV) or influenza virus, there was an increase in MAIT cell activation resulting in the production of IFN-γ, TNF-α and granzyme B, and up-regulation of CD69 by MAIT cells.48 In that study, it was further shown that the replication of HCV in liver hepatocytes was restricted by activated MAIT cells. When co-cultured with monocytes that were activated through stimulation of TLR8 ligand (single-stranded RNA), MAIT cells were activated to produce IFN-γ and Granzyme B, and activation was higher than co-culturing MAIT cells with supernatants obtained from TLR8-stimulated monocytes.21 These findings suggest monocytes activate MAIT cells in both a contact-dependent (even in absence of Ag presentation on MR1) and -independent manner. MAIT cell were activated to a similar degree when co-cultured with influenza-infected monocytes or monocyte-derived macrophages, driven mostly by IL-18 cytokine.48,54

Changes in MAIT cell numbers and function in disease states

MAIT cells can be found in blood, tissues and airways. These cells make up 1–10% of circulating T cells in peripheral blood, and up to 60% of T cells in liver and gastrointestinal tract.9,15,65-67 The frequencies of MAIT cells in peripheral blood is lower in patients

Table 1. Continued.

| Pathogen type or disease | Pathways of MAIT cell activation | Experimental system | Major findings | References |
|-------------------------|----------------------------------|---------------------|---------------|------------|
| Influenza virus         | IL-18 in synergy with IL-12 and IL-15 | Co-culture of PBMC-derived CD8+ MAIT cells with influenza-infected macrophages | MAIT cells were activated by influenza virus to produce IFN-γ and granzyme B | 48 |
|                         | IL-18                             | PBMCs co-cultured with influenza-infected epithelial cells | MAIT cells were protective against influenza infection in IL-18 dependent manner | 54 |
| Cancer                  | TCR dependent                     | Co-culture of influenza-infected monocytes with A549 MAIT cell line | As above | 54 |
|                         | TCR dependent                     | Cultured PBMCs      | MAIT cells infiltrated colorectal cancer tumors and were activated to cause cell cycle arrest reducing viability of tumor cells | 63 |
|                         | TCR dependent                     | Cultured colonic-derived cells | MAIT cells infiltrated colon tumors, displaying an activated memory phenotype with reduced IFN-γ production. | 64 |

HCV: Hepatitis C virus; DENV: Dengue virus; Mtb: Mycobacterium tuberculosis; BCG: Bacillus Calmette-Guerin; S. typhi: Salmonella enterica serovar Typhi.

*Experiments in animal model.

aExperiments in animal model.
with TB disease or HIV infection compared to healthy individuals without TB or HIV, respectively. Lower MAIT cell numbers in blood has also been described in patients with sepsis, cholera, and human T-lymphotropic virus type 1 (HTLV-1) infections, as well as non-infectious conditions such as diabetes, cystic fibrosis, autoimmunity, cancer and obesity. In contrast, MAIT cell numbers have been shown to increase in the lungs of patients with pulmonary TB, suggesting a role in local immune responses to the infection.

The reason for the decrease in MAIT cell numbers in the periphery in these conditions is not well understood. It has been suggested that the decrease in MAIT cell frequencies in blood could be due to redistribution to tissues, activation-induced cell death or down-regulation of receptors used to identify these cells, such as CD161. The recent development of the MR1 Ag-loaded tetramers may add clarity to the above conflicting findings by improved identification of MAIT cells in situations where CD161 is down-regulated, compromising detection by mAbs. Frequencies of MAIT cells have been shown to decrease in peripheral blood of individuals infected with S. typhi and H. pylori but their functional capacity (cytokine production, activation or proliferation) increased compared with uninfected individuals.

There have been conflicting reports in HCV infection whether MAIT cells increase or decrease in liver compared to the periphery. Eberhard et al. described a decrease in MAIT cells (defined as CD4^+CD3^+CD161^−Vα7.2^+) frequencies in the liver, while Bilerbeck et al. described an enrichment of MAIT cells (defined as CD3^+CD8^+CD161^+) in the liver compared with blood. The differences in MAIT cell definition might contribute to the conflicting findings.

Even though it is well described that MAIT cell frequencies in blood decrease in certain diseases, the function of these cells during infection and other diseases is not yet well described. Studies report conflicting findings regarding functional attributes (e.g. level of cytokine production) of MAIT cells in TB disease in blood and this may relate to pathogen used for ex vivo stimulation.23 A decrease in IFN-γ production by MAIT cells in blood was described in TB patients compared with healthy controls upon E. coli stimulation, and this was associated with an increase in PD-1 expression in these cells. Upon BCG stimulation, MAIT cells from TB patients exhibited an increase in IFN-γ and TNF-α production while E. coli stimulation in the same patients was associated with a decrease in cytokine production. Upon PD-1 blockade followed by BCG or E. coli stimulation, MAIT cells from TB patients exhibited an increase in IFN-γ production in comparison to no PD-1 blockade. Increased production of cytokines, granzyme B and up-regulation of the activation markers (HLA-DR and CD38) by MAIT cells has also been described in chronic HCV and DENV infection in an IL-18-dependent manner, despite the decrease in frequencies of MAIT cells. One study in HIV infection reported that despite an early depletion, MAIT cells remained highly activated (high expression of HLA-DR and CD38) and their functional capacity (IFN-γ production) was retained up to 2 yr after HIV seroconversion.

**MAIT cell activation and function in infectious diseases**

The activation of MAIT cells by bacterial and viral pathogens suggest that these cells could play a role in preventing the establishment of infection after exposure or preventing progression from infection to disease, in the case of TB, for example. BCG vaccination in non-human primates resulted in activation of MAIT cells in blood 14- to 28-d post vaccination but conventional non-MAIT CD8^+ T cells were not activated. MAIT cells were also found to proliferate more, became more activated and expressed higher granzyme B at the site of vaccination (chest) with BCG compared to distal site (thigh). When macaques were infected with Mb, MAIT cells proliferated more in blood, but the level of activation was similar to that of conventional non-MAIT CD8^+ cells.

Kwon et al. and Jiang et al. showed that MAIT cell responses to bacteria in pulmonary TB patients were functionally defective compared to healthy controls, but similar in people with non-tuberculous mycobacteria suggesting the inhibitory effect of mycobacterial disease on MAIT cell function. A polymorphism on MR1 has been linked to altered MR1 expression, susceptibility to TB and death from meningeval TB. The minor allele genotype of the polymorphism was associated with increased susceptibility to meningeval TB and higher MR1 expression, suggesting over-activation of MAIT cells may promote inflammation, which may paradoxically be detrimental by resulting in bacterial dissemination from lungs to extra pulmonary sites including the central nervous system. A possible increase in cerebral inflammation could also be a contributing factor. More studies are required to evaluate the association of MAIT cells with TB at presentation and disease outcome. Several other human studies (discussed above) have described the activation, functional and numerical changes in MAIT cells in patients with TB and other bacterial/viral diseases. So far, no human studies have associated MAIT cell function or numbers with clinical outcomes of disease or infection. MAIT cells have been shown to accumulate in the lungs of mice infected with S. typhi and this accumulation was dependent on MR1 and the size of bacterial inoculum. In addition, differentiation of monocytes to DCs in the lungs following Francisella tularensis infection and subsequent recruitment of CD4^+ T cells to the lung was mediated by...
MAIT cells. IL-12p40-, MR1- or MAIT cell-deficient mice lacked the ability to control BCG or *F. tularensis* infections and quickly succumbed to low doses of BCG infection.4,86

In a human challenge model, individuals were infected with high (10^6) and low (10^3) doses of *S. typhi* and followed up for up to 28 d for the development of typhoid fever.61 In individuals who developed the disease (compared with those that did not) there was an increase in proliferation (using Ki67), expression of CD38 and HLA-DR (activation markers), CD57 (exhaustion marker), and caspase 3 (apoptosis marker) on MAIT cells and these changes occurred 48–96 h after disease onset. In individuals infected with *H. pylori*, compared with uninfected individuals, MAIT cell numbers were lower in peripheral blood but not the gastric mucosa.56 However, MAIT cells in both peripheral blood and gastric mucosa were activated by *H. pylori*-infected macrophages in an MR1-dependent manner to express cytokines, CD107a and CD69, and these MAIT cells were also able to directly induce killing of the infected macrophages.56

Despite effective treatment (leading to significant improvement in CD4 counts and control of viraemia) for HIV for up to 4 yr, MAIT cell frequencies were still comparable to pre-treatment levels, but the function of these cells was partially restored.68,77,78 Similarly, the decrease in MAIT cell frequencies in HCV infection did not recover following successful 24-wk HCV therapy.62,79 Other evidence suggests that the decrease in MAIT cell numbers correlate with the type of bacterial disease and severity,70,75,80 and numbers may rise upon effective antibacterial treatment; patients whose MAIT cell numbers failed to rise upon treatment were more susceptible to further hospital acquired infections.70

**MAIT cell activation and function in cancer**

MAIT cells are also affected by cancer and other non-communicable diseases such as obesity, diabetes, autoimmunity, and asthma, and may play a role in the pathogenesis of these conditions.63,64,69–72,74–76,87 Changes in MAIT cell numbers and function have been reported in different forms of cancer.63,64,76,87 It was observed that the frequencies of circulating MAIT cells tend to decrease in patients with intestinal cancers such as colorectal cancer and gastric cancer, as well as lung cancers, compared to MAIT cells in healthy controls.76 On the contrary, for non-mucosal associated cancers such as liver and thyroid cancer, the frequencies and numbers of MAIT cells in circulation were similar to those of healthy controls, and higher than those of mucosal associated cancer patients.76 Despite a decrease in circulating MAIT cells, there was accumulation of MAIT cells in tumors.63,87 High frequencies of MAIT cells were observed in colorectal tumors compared to healthy colons, while frequencies of other T cell subsets were similar in these tissues.63,87

Cytokine production by MAIT cells either decreased or remained similar in cancer patients compared to healthy individuals. One study observed no significant difference in cytokine production by MAIT cells between cancer patients and healthy controls in responses to phorbol myristate acetate (PMA) and ionomycin,76 while other studies observed a lower IFN-γ and TNF-α production in tumor-associated MAIT cells compared to MAIT cells in unaffected mucosa.63,64 IL-17 production by MAIT cells was either higher in cancer patients compared with healthy controls,76 or similar.64

MAIT cells may have a direct cytotoxic effect on cancer cells. To assess their functions, Ling et al.63 and Won et al.76 co-cultured MAIT cells using HCT116 (human colon cancer cell line) and K562 (a human erythroleukemic cell line) cells. Activated MAIT cells produced cytokines (TNF-α, IFN-γ and IL-17), degranulated (increased CD107a expression) with up-regulation of cytotoxic markers (perforin and granzymes B) during co-culture, and had the capacity to cause cell cycle arrest of HCT116 at the G2/M cycle in a cell-cell contact-dependent manner, resulting in reduced viability of HCT116 and K562 cells.63,76

The infiltration of tumors by MAIT cells and the resulting cytokine and cytotoxic marker expression suggest that these cells play a role in anti-tumor immunity such as modeling the cytokine network and affecting the balance between tumor suppressing and promoting cytokines, and may also have a role in the development or the regulation of tumors, although their specific function and the interaction with innate cells in these processes still needs to be defined. An association of MAIT cell numbers with outcome in cancer has been suggested: an increase in MAIT cell infiltration of tumors correlated with poor survival in patients with colorectal cancer.57 However, the changes in MAIT cell function and numbers upon cancer treatment has not been described.

**Conclusion and future perspectives**

We have summarized here the existing (albeit limited) evidence that APCs can activate MAIT cells in both an MR1-dependent and independent manner. These studies have used mostly MR1 transfected cell lines, epithelial cells or heterologous systems where APCs are activated separately followed by co-culture of either infected cells or cell culture supernatants with MAIT cells. Studies assessing MAIT cell activation by APCs in an autologous system are lacking. Such studies are needed to more precisely define the interactions of
APCs with MAIT cells resulting in MAIT cell activation, as well as the relative contribution of the MR1-dependent and independent pathways of MAIT cell activation. Also, research is needed to understand how the magnitude of MAIT cell activation is related to the quality and quantity of innate cell activation and the magnitude of cytokine production by innate cells.

Despite several studies reporting the decrease in frequencies of MAIT cells in peripheral blood and some tissues in HIV, TB, other viral and non-communicable diseases, further studies are required to delineate the specific functions of MAIT cells compared with conventional T cells in these diseases and how they associate with presentation and outcome. To the best of our knowledge, no human studies have so far shown an association between alteration of MAIT cell function or numbers/frequencies with clinical outcomes such as protection from infection or development of disease. Even though MAIT cells seem to play a role in immune responses that may prevent infection or progression to disease, more studies are required to demonstrate this. A better understanding of the activation and function of MAIT cells in infectious and non-communicable diseases including HIV, TB, and cancer may lead to more targeted interventions to prevent or treat these diseases, such as the development of mucosal or systemic vaccines that specifically activate MAIT cells.

**Acknowledgments**

KAW was supported by the Foundation for Innovation and New Diagnostics, the European Union Horizon 2020 research and innovation programme (grant agreement No 64338). GM was supported by the Wellcome Trust (098316), the South African Research Chairs Initiative of the Department of Science and Technology and National Research Foundation (NRF) of South Africa (grant number 64787). NRF incentive funding (UID: 85858) and the South African Medical Research Council through its TB and HIV Collaborating Centres Programme with funds received from the National Department of Health (RFA# SAMRC-RFA-CC: TB/HIV/AIDS-01-2014). AF was supported by an NRF scholarship.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**ORCID iD**

Muki Shehu Shey  http://orcid.org/0000-0002-8776-4737

**References**

1. Iwasaki A and Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010; 327: 291–295.
2. Urdahl KB, Shafiiuni S and Ernst JD. Initiation and regulation of T-cell responses in tuberculosis. Mucosal Immunol 2011; 4: 289–293.
3. Godfrey DI, Uldrich AP, McCluskey J, et al. The burgeoning family of unconventional T cells. Nat Immunol 2015; 16: 1114–1123.
4. Chuai WJ, Truscott SM, Eichkoff CS, et al. Polyclonal mucosal-associated invariant T cells have unique innate functions in bacterial infection. Infect Immun 2012; 80: 3256–3267.
5. Tilloy F, Treiner E, Park SH, et al. An invariant T cell receptor alpha chain defines a novel TAP-independent major histocompatibility complex class Ib-restricted alpha/beta T cell subpopulation in mammals. J Exp Med 1999; 189: 1907–1921.
6. Gold MC and Lewinsohn DM. Co-dependents: MR1-restricted MAIT cells and their antimicrobial function. Nat Rev Microbiol 2013; 11: 14–19.
7. Le Bourhis L, Dusseaux M, Bohineust A, et al. MAIT cells detect and efficiently lyse bacterially-infected epithelial cells. PLoS Pathog 2013; 9: e1003681.
8. Le Bourhis L, Martin E, Peguillet I, et al. Antimicrobial activity of mucosal-associated invariant T cells. Nat Immunol 2010; 11: 701–708.
9. Treiner E. MAIT lymphocytes, regulators of intestinal immunity? Press Med 2003; 32: 1636–1637.
10. Kurioka A, Ussher JE, Cosgrove C, et al. MAIT cells are licensed through granzyme exchange to kill bacterially sensitized targets. Mucosal Immunol 2015; 8: 429–440.
11. Billerbeck E, Kang YH, Walker L, et al. Analysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties. Proc Natl Acad Sci USA 2010; 107: 3006–3011.
12. Gold MC, Cerri S, Smyk-Pearson S, et al. Human mucosal associated invariant T cells detect bacterially infected cells. PLoS Biol 2010; 8: e1000407.
13. Sharma PK, Wong EB, Napier RJ, et al. High expression of CD26 accurately identifies human bacteria-reactive MR1-restricted MAIT cells. ImmunoL 2015; 145: 443–453.
14. Corbett AJ, Ecke SB, Birkinshaw RW, et al. T-cell activation by transitory neo-antigens derived from distinct microbial pathways. Nature 2014; 509: 361–365.
15. Reantragoon R, Corbett AJ, Sakala IG, et al. Antigen-loaded MR1 tetramers define T cell receptor heterogeneity in mucosal-associated invariant T cells. J Exp Med 2013; 210: 2305–2320.
16. Gold MC, McLaren JE, Reisterter JA, et al. MR1-restricted MAIT cells display ligand discrimination and pathogen selectivity through distinct T cell receptor usage. J Exp Med 2014; 211: 1601–1610.
17. Kjer-Nielsen L, Patel O, Corbett AJ, et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature 2012; 491: 717–723.
18. Jiang J, Chen X, An H, et al. Enhanced immune response of MAIT cells in tuberculous pleural effusions depends on cytokine signaling. Sci Rep 2016; 6: 32320.
19. Leeansyah E, Svard J, Dias J, et al. Arming of MAIT cell cytolytic antimicrobial activity is induced by IL-7 and defective in HIV-1 infection. PLoS Pathog 2015; 11: e1005072.
20. Gibbs A, Leeansyah E, Intromini A, et al. MAIT cells reside in the female genital mucosa and are biased towards IL-17 and IL-22 production in response to bacterial stimulation. Mucosal Immunol 2017; 10: 35–45.
21. Slichter CK, McDavid A, Miller HW, et al. Distinct activation thresholds of human conventional and innate-like memory T cells. JCI Insight 2016; 1(8): e86292.
22. Ussher JE, Bilton M, Attwood E, et al. CD161++ CD8+ T cells, including the MAIT cell subset, are specifically activated by IL-12+ IL-18 in a TCR-independent manner. *Eur J Immunol* 2014; 44: 195–203.

23. Jiang J, Wang X, An H, et al. Mucosal-associated invariant T-cell function is modulated by programmed death-1 signaling in patients with active tuberculosis. *Am J Respir Crit Care Med* 2014; 190: 329–339.

24. Shaler CR, Choi J, Rudak PT, et al. MAIT cells launch a rapid, robust and distinct hyperinflammatory response to bacterial superantigens and quickly acquire an agnostic phenotype that impedes their cognate antimicrobial function: Defining a novel mechanism of superantigen-induced immunopathology and immunosuppression. *PLoS Biol* 2017; 15: e2001930.

25. Banchereau J and Steinman RM. Dendritic cells and the control of immunity. *Nature* 1998; 392: 245–252.

26. Muller-Trutwin M and Hosmalin A. Role for plasmacytoid dendritic cells in anti-HIV innate immunity. *Immunol Cell Biol* 2005; 83: 578–583.

27. Shey MS, Garrett NJ, McKinnon LR, et al. The role of dendritic cells in driving genital tract inflammation and HIV transmission risk: are there opportunities to intervene? *Innate Immun* 2015; 21: 99–112. 2013/11/28.

28. Tsukamoto M, Seta N, Yoshimoto K, et al. CD14brightCD16+ intermediate monocytes are induced by interleukin-10 and positively correlate with disease activity in rheumatoid arthritis. *Arthritis Res Ther* 2017; 19: 28.

29. Ziegler-Heitbrock L, Ancuta P, Crowe S, et al. Nomenclature of monocytes and dendritic cells in blood. *Blood* 2010; 116: e74–80.

30. de Wit J, Jorritsma T, Makuch M, et al. Human B cells promote T-cell plasticity to optimize antibody response by inducing coexpression of T(H1)/(T(H)F) signatures. *J Allergy Clin Immunol* 2015; 135: 1053–1060.

31. de Wit J, Souwer Y, Jorritsma T, et al. Antigen-specific B cells reactivate an effective cytotoxic T cell response against phagocytosed Salmonella through cross-presentation. *PLoS One* 2010; 5: e13016.

32. Aldemir H, Prod’homme V, Dumaurier MJ, et al. Cutting edge: lectin-like transcript 1 is a ligand for the CD161 receptor. *J Immunol* 2005; 175: 7791–7795.

33. Rosen DB, Bettadapura J, Alsharifi M, et al. Cutting edge: lectin-like transcript-1 is a ligand for the inhibitory human NKR-P1A receptor. *J Immunol* 2005; 175: 7796–7799.

34. Rosen DB, Cao W, Avery DT, et al. Functional consequences of interactions between human NKR-P1A and its ligand LLT1 expressed on activated dendritic cells and B cells. *J Immunol* 2008; 180: 6508–6517.

35. Treiner E, Duban L, Bahram S, et al. Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1. *Nature* 2003; 422: 164–169.

36. Seder RA, Gazzinelli R, Sher A, et al. Interleukin 12 acts directly on CD4+ T cells to enhance priming for interfor gamma production and diminishes interleukin 4 inhibition of such priming. *Proc Natl Acad Sci USA* 1993; 90: 10188–10192.

37. Luzio JP, Pryor PR and Bright NA. Lysosomes: fusion and function. *Nat Rev Mol Cell Biol* 2007; 8: 622–632. 2007/07/20.

38. Gutcher I and Becher B. APC-derived cytokines and T cell polarization in autoimmune inflammation. *J Clin Invest* 2007; 117: 1119–1127.

39. Blanchet J, Jaramillo M and Olivier M. Signalling events involved in interferon-gamma-inducible macrophage nitric oxide generation. *Immunology* 2003; 108: 513–522.

40. Oykhman P and Mody CH. Direct microbicidal activity of cytotoxic T-lymphocytes. *J Biomed Biotechnol* 2010; 2010: 249482.

41. Athie-Morales V, Smits HH, Cantrell DA, et al. Sustained IL-12 signaling is required for Th1 development. *J Immunol* 2004; 172: 61–69.

42. Cooper AM, Solache A and Khader SA. Interleukin-12 and tuberculosis: an old story revisited. *Curr Opin Immunol* 2007; 19: 441–447.

43. Villinger F and Ansari AA. Role of IL-12 in HIV infection and vaccine. *Eur Cytokine Netw* 2010; 21: 215–218.

44. Nag-Agren SE and Cooney EL. Interleukin-12 enhancement of antigen-specific lymphocyte proliferation correlates with stage of human immunodeficiency virus infection. *J Infect Dis* 1999; 179: 493–496.

45. Ahmad R, Sindhu ST, Toma E, et al. Elevated levels of circulating interleukin-18 in human immunodeficiency virus-infected individuals: role of peripheral blood mononuclear cells and implications for AIDS pathogenesis. *J Virol* 2002; 76: 12448–12456.

46. Schneider BE, Korbel D, Hagens K, et al. A role for IL-18 in protective immunity against Mycobacterium tuberculosis. *Eur J Immunol* 2010; 40: 396–405.

47. Cooper AM, Magram J, Ferrante J, et al. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with mycobacterium tuberculosis. *J Exp Med* 1997; 186: 39–45.

48. van Wilgenburg B, Scherwitzl I, Hutchinson EC, et al. MAIT cells are activated during human viral infections. *Nat Commun* 2016; 7: 11653.

49. Shey MS, Nemes E, Whatney W, et al. Maturation of innate responses to mycobacteria after the first nine months of life. *J Immunol* 2014; 192: 4833–4843.

50. Ussher JE, van Wilgenburg B, Hanaway RF, et al. TLR signaling in human antigen-presenting cells regulates MR1-dependent activation of MAIT cells. *Eur J Immunol* 2016; 46: 1600–1614.

51. Harriff MJ, Karamooz E, Burr A, et al. Endosomal MR1 Trafficking Plays a Key Role in Presentation of Mycobacterium tuberculosis Ligands to MAIT Cells. *PLoS Pathog* 2016; 12: e1005524.

52. Chua WJ, Kim S, Myers N, et al. Endogenous MHC-related protein 1 is transiently expressed on the plasma membrane in a conformation that activates mucosal-associated invariant T cells. *J Immunol* 2011; 186: 4744–4750.

53. Salerno-Goncalves R, Rezwan T and Szeint MB. B cells modulate mucosal associated invariant T cell immune responses. *Front Immunol* 2014; 4: 511.

54. Loh L, Wang Z, Sant S, et al. Human mucosal-associated invariant T cells contribute to antiviral influenza immunity via IL-18-dependent activation. *Proc Natl Acad Sci USA* 2016; 113: 10133–10138.

55. Dias J, Sobkowiak MJ, Sandberg JK, et al. Human MAIT-cell responses to *Escherichia coli*: activation, cytokine production, proliferation, and cytotoxicity. *J Leukoc Biol* 2016; 100: 233–240.

56. Booth JS, Salerno-Goncalves R, Blanchard TG, et al. Mucosal-associated invariant T cells in the human gastric mucosa and blood: role in *Helicobacter pylori* infection. *Front Immunol* 2015; 6: 466.

57. Liu J and Brutkiewicz RR. The Toll-like receptor 9 signalling pathway regulates MR1-mediated bacterial antigen presentation in B cells. *Immunology* 2017; 152: 232–242.

58. Salio M, Gasser O, Gonzalez-Lopez C, et al. Activation of human mucosal-associated invariant T cells induces CD40L-dependent maturation of monoocyte-derived and primary dendritic cells. *J Immunol* 2017; 199: 2631–2638.

59. Greene JM, Dash P, Roy S, et al. MR1-restricted mucosal-associated invariant T (MAIT) cells respond to mycobacterial vaccination and infection in nonhuman primates. *Mucosal Immunol* 2017; 10: 802–813.

60. Dias J, Leansyah E and Sandberg JK. Multiple layers of heterogeneity and subset diversity in human MAIT cell responses to distinct microorganisms and to innate cytokines. *Proc Natl Acad Sci USA* 2017; 114: E5434–E5443.
61. Salerno-Goncalves R, Luo D, Fresnay S, et al. Challenge of humans with wild-type Salmonella enterica Serovar typhi elicits changes in the activation and homing characteristics of mucosal-associated invariant T cells. *Front Immunol* 2017; 8: 398.

62. Spaan M, Hullegie SJ, Beudeker BJ, et al. Frequencies of circulating MAIT cells are diminished in chronic HCV, HIV and HCV/HIV co-infection and do not recover during therapy. *PLoS One* 2016; 11: e0159243.

63. Ling L, Lin Y, Zheng W, et al. Circulating and tumor-infiltrating mucosal associated invariant T (MAIT) cells in colorectal cancer patients. *Sci Rep* 2016; 6: 20358.

64. Sundstrom P, Ahlmann F, Akeus P, et al. Human mucosa-associated invariant T cells accumulate in colon adenocarcinomas but produce reduced amounts of IFN-gamma. *J Immunol* 2015; 195: 3472–3481.

65. Dusseaux M, Martin E, Serriari N, et al. Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. *Blood* 2011; 117: 1250–1259.

66. Jo J, Tan AT, Ussher JE, et al. Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver. *PLoS Pathog* 2014; 10: e1004210.

67. Martin E, Treiner E, Duban L, et al. Stepwise development of MAIT cells in mouse and human. *PLoS Biol* 2009; 7: e54.

68. Wong EB, Akilimali NA, Govender P, et al. Low levels of peripheral CD161 + + CD8 + mucosal associated invariant T (MAIT) cells are found in HIV and HIV/TB co-infection. *PLoS One* 2013; 8: e83474.

69. Cho YN, Kee SJ, Kim MJ, et al. Mucosal-associated invariant T cell deficiency in systemic lupus erythematosus. *J Immunol* 2014; 193: 3891–3901.

70. Grimaldi D, Le Bourhis L, Sauneuf B, et al. Specific MAIT cell behaviour among innate-like T lymphocytes in critically ill patients with severe infections. *Intensive Care Med* 2014; 40: 192–201.

71. Leung DT, Bhuian TR, Nisht NS, et al. Circulating mucosal associated invariant T cells are activated in Vibrio cholerae O1 infection and associated with lipopolysaccharide antibody responses. *PLoS Negl Trop Dis* 2014; 8: e3076.

72. Magalhaes I, Pingris K, Poitou C, et al. Mucosal-associated invariant T cell alterations in obese and type 2 diabetic patients. *J Clin Invest* 2015; 125: 1752–1762.

73. Paquin-Proulx D, Greenspun BC, Costa EA, et al. MAIT cells are reduced in frequency and functionally impaired in human T lymphotrophic virus type 1 infection: Potential clinical implications. *PLoS One* 2017; 12: e0175345.

74. Serriari NE, Eoche M, Lamotte L, et al. Inadequate mucosal-associated invariant T (MAIT) cells are activated in inflammatory bowel diseases. *Clin Exp Immunol* 2014; 176: 266–274.

75. Smith DJ, Hill GR, Bell SC, et al. Reduced mucosal associated invariant T-cells are associated with increased disease severity and *Pseudomonas aeruginosa* infection in cystic fibrosis. *PLoS One* 2014; 9: e109891.

76. Won EJ, Ju JK, Cho YN, et al. Clinical relevance of circulating mucosal-associated invariant T cell levels and their anti-cancer activity in patients with mucosal-associated cancer. *Oncotarget* 2016; 7: 76274–76290.

77. Cosgrove C, Ussher JE, Rauch A, et al. Early and nonreversible decrease of CD161 + + MAIT cells in HIV infection. *Blood* 2013; 121: 951–961.

78. Leeney SA, Ganesh A, Quigley MF, et al. Activation, exhaustion, and persistent decline of the antimicrobial MR1-restricted MAIT-cell population in chronic HIV-1 infection. *Blood* 2013; 121: 1124–1135.

79. Eberhard JM, Kummer S, Hartjen P, et al. Reduced CD161 + MAIT cell frequencies in HCV and HIV/HCV co-infection: Is the liver the heart of the matter? *J Hepatol* 2016; 65: 1261–1263.

80. Kwon YS, Cho YN, Kim MJ, et al. Mucosal-associated invariant T cells are numerically and functionally deficient in patients with mycobacterial infection and reflect disease activity. *Tuberculosis (Edinb)* 2015; 95: 267–274.

81. Fernandez CS, Amarasena T, Kelleher AD, et al. MAIT cells are depleted early but retain functional cytokine expression in HIV infection. *Immunol Cell Biol* 2015; 93: 177–188.

82. Jiang J, Yang B, An H, et al. Mucosal-associated invariant T cells from patients with tuberculosis exhibit impaired immune response. *J Infect* 2016; 72: 338–352.

83. Seshadri C, Thuong NT, Mai NT, et al. A polymorphism in human MR1 is associated with mRNA expression and susceptibility to tuberculosis. *Genes Immun* 2017; 18: 8–14.

84. Chen Z, Wang H, D’Souza C, et al. Mucosal-associated invariant T-cell activation and accumulation after in vivo infection depends on microbial riboflavin synthesis and co-stimulatory signals. *Mucosal Immunol* 2017; 10: 58–68.

85. Meierovics AI and Cowley SC. MAIT cells promote inflammatory monocyte differentiation into dendritic cells during pulmonary intracellular infection. *J Exp Med* 2016; 213: 2793–2809.

86. Meierovics A, Yankelevich WJ and Cowley SC. MAIT cells are critical for optimal mucosal immune responses during in vivo pulmonary bacterial infection. *Proc Natl Acad Sci USA* 2013; 110: E3119–3128.

87. Zabijak L, Attencourt C, Guignant C, et al. Increased tumor infiltration by mucosal-associated invariant T cells correlates with poor survival in colorectal cancer patients. *Cancer Immunol Immunother* 2015; 64: 1601–1608.